OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ in London and Boston
Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.